

## Correction of the Hemostatic Potential of the Blood in Conditions of Thrombocytopenia in Patients With Idiopathic Thrombocytopenic Purpura

*Abdiyev Kattabek Makhmatovich*<sup>1</sup>, *Abdullayeva Gulrukh Izatillo kizi*<sup>2</sup>, *Kudratova Farangiz Mardonovna*<sup>3</sup>

**Abstract:** For gentle cases, cautious perception might be adequate. Notwithstanding, in examples of extremely low platelet counts or huge dying, treatment choices might incorporate corticosteroids, intravenous immunoglobulin, against D immunoglobulin, or immunosuppressive prescriptions. Hard-headed ITP, which doesn't answer traditional treatment or shows consistent backslide after splenectomy, expects treatment to diminish the gamble of critical dying. Platelet bondings might be utilized in serious cases with very low platelet includes in people encountering dying. Now and again, the body might repay by delivering strangely enormous platelets.

**Keywords:** Resistant thrombocytopenic purpura, condition, symptoms, surgery, injury.

### INTRODUCTION

Resistant thrombocytopenic purpura (ITP), otherwise called idiopathic thrombocytopenic purpura or safe thrombocytopenia, is a sort of thrombocytopenic purpura described by a low platelet include without different causes, and joined by a red-purple rash called purpura [1. 43p]. It prompts an expanded gamble of dying. ITP appears in two particular clinical disorders: an intense structure saw in youngsters, and persistent circumstances saw in grown-ups. The intense structure frequently follows a disease and commonly settle in the span of two months, while ongoing safe thrombocytopenia perseveres for longer than a half year and its particular reason is obscure.

ITP is viewed as an immune system infection, as antibodies against a few platelet surface designs (antigens) can be distinguished.

Conclusion of ITP includes recognizing a low platelet count through a total blood count, a typical blood test. Be that as it may, since the conclusion depends on barring other expected reasons for a low platelet count, extra examinations, like a bone marrow biopsy, might be fundamental in specific cases.

### MAIN PART

#### Signs and symptoms

Indications of ITP incorporate the unconstrained development of injuries (purpura) and petechiae (minuscule injuries), particularly on the limits. Moreover, draining from the nostrils or potentially gums, as well as menorrhagia (exorbitant feminine dying), may happen on the off chance that the platelet count falls under 20,000 for each  $\mu\text{l}$  [4. 45p] A platelet count under 10,000 for every  $\mu\text{l}$  can prompt the unconstrained development of hematomas (blood masses) in the mouth or on other mucous layers. Besides, draining time from minor slashes or scraped areas is generally prolonged.

In situations where platelet counts drop to very low levels ( $<5,000$  per  $\mu\text{l}$ ), serious and possibly deadly confusions might emerge. These intricacies incorporate subarachnoid or intracerebral drain (draining inside the skull or cerebrum), lower gastrointestinal dying, or other inward dying. An individual with ITP with a very low platelet count is vulnerable to inside draining coming about because of obtuse

<sup>1</sup> Associate Professor of the Department of Hematology Samarkand State Medical University

<sup>2</sup> Student of group 401 of the Faculty of Medical Biology Samarkand State Medical University

<sup>3</sup> Student of group 401 of the Faculty of Medical Biology Samarkand State Medical University



stomach injury, for example, in an engine vehicle crash. These complexities are probably not going to happen when the platelet count is under 20,000 for every  $\mu\text{l}$  [5. 67p].

In around 60% of cases, antibodies against platelets can be detected [6. 34p]. Most frequently these antibodies are against platelet layer glycoproteins IIb-IIIa or Ib-IX, and are of the immunoglobulin G (IgG) type. The Harrington-Hollingsworth try laid out the resistant pathogenesis of ITP [7. 65p].

### Pathogenesis

The covering of platelets with IgG renders them defenseless to opsonization and phagocytosis by splenic macrophages, also by Kupffer cells in the liver. The IgG autoantibodies are additionally remembered to harm megakaryocytes, the antecedent cells to platelets, albeit this is accepted to contribute just somewhat to the decline in platelet numbers. Late exploration currently demonstrates that hindered creation of the glycoprotein chemical, thrombopoietin, which is the energizer for platelet creation, might be a contributing component to the decrease in flowing platelets. This perception has prompted the improvement of a class of ITP-designated drugs alluded to as thrombopoietin receptor agonists [5. 67p].

The upgrade for auto-immunizer creation in ITP is likely strange Lymphocyte activity. Preliminary discoveries propose that these Lymphocytes can be impacted by meds that target B cells, for example, rituximab.

The finding of ITP is a course of rejection. In the first place, it must be resolved that there are no blood irregularities other than a low platelet count, and no actual signs other than dying. Then, optional causes (5-10 percent of thought ITP cases) ought to be avoided. Such optional causes incorporate leukemia, meds (e.g., quinine, heparin), lupus erythematosus, cirrhosis, HIV, hepatitis C, inborn causes, antiphospholipid disorder, von Willebrand factor inadequacy, onyalai and others [4. 87p]. All patients with assumed ITP ought to be tried for HIV and hepatitis C infection, as platelet counts might be rectified by treating the fundamental sickness. In roughly 2.7 to 5 percent of cases, immune system hemolytic paleness and ITP coincide, a condition alluded to as Evans syndrome.

In spite of the obliteration of platelets by splenic macrophages, the spleen is ordinarily not extended. As a matter of fact, an extended spleen ought to prompt a quest for other potential reasons for the thrombocytopenia. Draining time is normally delayed in ITP patients. Nonetheless, the utilization of draining time in conclusion is deterred by the American Culture of Hematology practice guidelines and an ordinary draining time doesn't prohibit a platelet disorder.

Bone marrow assessment might be performed on patients beyond 60 years old and the people who don't answer treatment, or when the finding is in doubt. [3. 12p]. On assessment of the marrow, an expansion in the creation of megakaryocytes might be noticed and may help in laying out a conclusion of ITP. An investigation for hostile to platelet antibodies involves clinician's inclination, as there is conflict on whether the 80% explicitness of this test is adequate to be clinically useful.

With uncommon special cases, there is typically compelling reason need to treat in light of platelet counts. Numerous more seasoned proposals recommended a specific platelet count limit (typically some place underneath  $20.0/\mu\text{l}$ ) as a sign for hospitalization or treatment. Current rules suggest treatment just in instances of huge dying. Treatment suggestions now and again vary for grown-up and pediatric ITP.

### Steroids

Starting treatment normally comprises of the organization of corticosteroids, a gathering of drugs that stifle the safe framework. The portion and method of not entirely settled by platelet count and whether there is dynamic dying: in dire circumstances, mixtures of dexamethasone or methylprednisolone might be utilized, while oral prednisone or prednisolone might get the job done in less serious cases. When the platelet count has improved, the portion of steroid is step by step diminished while the chance of backslide is observed. 60-90 percent will encounter a backslide during portion decrease or



cessation. Long haul steroids are kept away from if conceivable due to potential secondary effects that incorporate osteoporosis, diabetes and cataracts.

### Against D

Another choice, appropriate for Rh-positive patients with practical spleens is intravenous organization of Rho (D) resistant globulin [Human; Against D]. The system of activity of against D isn't completely perceived. Be that as it may, following organization, against D-covered red platelet edifices soak Fc $\gamma$  receptor locales on macrophages, bringing about particular annihilation of red platelets (RBCs), consequently saving neutralizer covered platelets. There are two enemy of D items showed for use in patients with ITP: WinRho SDF and Rhophylac. The most widely recognized unfavorable responses are migraine (15%), sickness/heaving (12%) chills (<2%) and fever (1%).

### Steroid-saving specialists

There is expanding utilization of immunosuppressants, for example, mycophenolate mofetil and azathioprine in light of their adequacy. In persistent recalcitrant cases, where resistant pathogenesis has been confirmed, the off-name utilization of the vinca alkaloid and chemotherapy specialist vincristine might be attempted. Notwithstanding, vincristine has critical side effects and its utilization in treating ITP should be drawn closer with alert, particularly in youngsters.

### Intravenous immunoglobulin

Intravenous immunoglobulin (IVIg) might be implanted at times to diminish the rate at which macrophages consume counter acting agent labeled platelets. Notwithstanding, while here and there successful, exorbitant and produces improvement for the most part endures under a month. By and by, on account of an ITP patient previously planned for a medical procedure who has a perilously low platelet count and has encountered an unfortunate reaction to different therapies, IVIg can quickly increment platelet counts, and can likewise assist with diminishing the gamble of significant draining by momentarily expanding platelet counts.

## CONCLUSION

The death rate due to ongoing ITP fluctuates however will in general be higher comparative with everybody for any age range. In a review directed in Extraordinary England, it was noticed that ITP causes a roughly 60 percent higher pace of mortality contrasted with sex-and age-matched subjects without ITP. This expanded gamble of death with ITP is generally gathered in the moderately aged and older. 96% of announced ITP-related passings were people 45 years or more seasoned. No tremendous distinction was noted in the pace of endurance among guys and females.

## REFERENCES:

1. Pietras, Nicole M.; Pearson-Shaver, Anthony L. (2022). "Immune Thrombocytopenic Purpura". StatPearls. StatPearls Publishing.
2. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. (March 2009). "Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group". *Blood*. 113 (11): 2386–93. Doi: 10.1182/blood-2008-07-162503. PMID 19005182.
3. Lambert MP, Gernsheimer TB (May 2017). "Clinical updates in adult immune thrombocytopenia". *Blood*. 129 (21): 2829–2835. Doi: 10.1182/blood-2017-03-754119. PMC 5813736. PMID 28416506.
4. Cines DB, McMillan R (2005). "Management of adult idiopathic thrombocytopenic purpura". *Annual Review of Medicine*. 56: 425–42. Doi: 10.1146/annurev.med.56.082103.104644. PMID 15660520.
5. "Immune Thrombocytopenic Purpura". The Lecturio Medical Concept Library. Retrieved 27 July 2021.



6. Coopamah MD, Garvey MB, Freedman J, Semple JW (January 2003). "Cellular immune mechanisms in autoimmune thrombocytopenic purpura: An update". *Transfusion Medicine Reviews*. 17 (1): 69–80. Doi: 10.1053/tmrv.2003.50004. PMID 12522773.
7. Schwartz RS (November 2007). "Immune thrombocytopenic purpura--from agony to agonist". *The New England Journal of Medicine*. 357 (22): 2299–301. Doi: 10.1056/NEJMe0707126. PMID 18046034. S2CID 9765360.
8. Ibatova, S. M., & Mamatkulova, F. K. (2023). SOME FEATURES OF HEMOCOAGULATION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE. *Academia Science Repository*, 4(6), 89-96.
9. Ibatova, S. M., Mamatkulova, F. K., & Ruzikulov, N. Y. (2020). The clinical picture of acute obstructive bronchitis in children and the rationale for immunomodulatory therapy. *International Journal of Current Research and Review*, 12(17), 152-155.

